For further information please fill the details below:

First Name
Last Name
Mobile Number
Email Address
Program Enquired
School Enquired
Home >
Dr. Devendra Kumar

Dr. Devendra Kumar

Assistant professor
Pharmaceutical Chemistry
M. Pharm, Ph.D., Postdoctoral research

Areas of specialization: Pharmaceutical Chemistry


Academic:2 years

Research experience: 3.9 years

Interest areas:

  • Alzheimer's disease and developed CNS-active small molecules as Acetylcholine, Butyl choline, Beta-secretase 1, Matrix Metalloprotein-2 and 9 inhibitors and NMDA receptor antagonist.
  • Development of novel polymers, peptides as the carrier of CRISPR for the Brain delivery.
  • Development of small molecules for the management of Fragile X Syndrome.
  • Identification of spine abnormality and study of Microglia-Neuron communication in Fragile X Syndrome.
  • Behavioural studies in genetically modified animals for Alzheimer's disease andFragile X Syndrome.



  • Development of enzyme sensitive smart polymer for drug delivery (PI, 2.75 lacks, DIT University).
  • Development of Dual Amyloid β Aggregation Modulators and Metal Chelators as Neuroprotective Agents for the Treatment of Alzheimer’s Disease (Co-PI, 2.5 lacks, DIT University).


  • A pharmaceutical composition of sulfonamide derivatives for the treatment of Alzheimer’s disease (Indian, Granted).
  • Novel Quinolinyl Piperazine derivatives for the treatment of Alzheimer’s disease (Indian, Application No. 201911032481).
  • Novel sulfonamide derivatives of para amino benzoic acid for the treatment of Alzheimer’s disease (Indian, Application No. 201911044199).
  • Multitarget-directed triazole bridged cycloaryl analogues for treatment of Alzheimer’s disease (Indian, Application No. 202011047641).
  • Novel Adamantyl analogues as multitargeting agents for the treatment of Alzheimer's disease (Indian, Application no. 202211028434).
  • Novel Triazole Adamantyl analogues as multitargeting agent for the treatment of Alzheimer's disease (Indian, Application no. 202211028432).
  • Novel non-aromatic Quinolinyl Piprazine derivatives as multitargeting agents for the treatment of Alzheimer's disease (Indian, Application no. 202211028433).

Books/Book chapters published

Aspartic proteases: Potential drug targets for anticancer drug development. Ankit Ganeshpurkar, Makar S, Devendra Kumar, Jana S, Singh SK. In Cancer-Leading Proteases 2020 Jan 1 (pp. 121-163), ISBN No. 978-0-12-818168-3. Academic Press.

Number of Publications: 39

Recent Publications: 

  1. Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer’s: Design, Synthesis, and Biological Evaluation. Gupta SM, Behera A, Jain NK, Devendra Kumar, Tripathi A, Tripathi SM, Mujwar S, Patra J, Negi A. Pharmaceutics. 2023 Jan;15(1):94.
  2. Identification of potential death-associated protein kinase-1 (DAPK1) inhibitors by an integrated ligand-based and structure-based computational drug design approach. Ghosh P, Singh R, Ganeshpurkar A, Swetha R, Devendra Kumar, Singh SK, Kumar A. Journal of Biomolecular Structure and Dynamics. 2022 Dec 15:1-3.
  3. Preclinical Models for Alzheimer’s Disease: Past, Present, and Future Approaches. Akhtar A, Gupta SM, Dwivedi S, Kumar D, Shaikh MF, Negi A. ACS Omega. 2022 Dec 13.
  4. Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer’s disease. Swetha R, Sharma A, Singh R, Ganeshpurkar A, Kumar D, Kumar A, Singh SK. Molecular Diversity. 2022 Aug 6:1-6.
  5. Identification of sulfonamide based butyrylcholinesterase inhibitors through scaffold hopping approach. Ankit Ganeshpurkar, Ravi Singh, Devendra Kumar, Gore P, Shivhare S, Sardana D, Rayala S, Kumar A, Sushil Kumar Singh. International Journal of Biological Macromolecules. 2022 Jan 26.
  6. Centella asiatica Alleviates AlCl3-induced Cognitive Impairment, Oxidative Stress, and Neurodegeneration by Modulating Cholinergic Activity and Oxidative Burden in Rat Brain. Zeba Firdaus, Devendra Kumar, Sushil Kumar Singh & Tryambak Deo Singh. Biological Trace Element Research. 2022 Jan 4:1-2.
  7. Classification of BACE1 inhibitors by using machine learning methods. Ravi Singh, Ankit Ganeshpurkar, Powsali Ghosh, Ankit Vyankatrao Pokle, Devendra Kumar, Ravi bhushan Singh, Sushil Kumar Singh, Ashok Kumar. Chemical Biology & Drug Design. 2021 Dec;98(6):1079-97.
  8. Improved machine learning scoring functions for identification of Electrophorus electricus’s acetylcholinesterase inhibitors. Ankit Ganeshpurkar, Ravi Singh, Shalini Shivhare, Divya, Devendra Kumar, Gopichand Gutti, Ravi bhushan Singh, Ashok Kumar, Sushil Kumar Singh. Molecular Diversity. 2021 Jul 30:1-25.
  9. Computational binding study with α7 nicotinic acetylcholine receptor of Anvylic-3288: an allosteric modulator. Ankit Ganeshpurkar, Ravi Singh, Devendra Kumar, Divya, Shivhare S, Ashok Kumar, Sushil Kumar Singh. Molecular Simulation. 2020 Jul 23:1-12.
  10. Highly fluorescent carbon dots from wheat bran as a novel drug delivery system for bacterial inhibition. John, Titto Sunil, Pradeep Kumar Yadav, Devendra Kumar, Sushil Kumar Singh, and Syed Hadi Hasan. Luminescence. 2020 Sep;35(6):913-23.
  11. Structure-based screening and molecular dynamics simulation studies for the identification of potential acetylcholinesterase inhibitors. Ankit Ganeshpurkar, Ravi Singh , Gore Pravin Gangaram, Devendra Kumar, Gopichand Gutti, Ashok Kumar, Sushil Kumar Singh. Molecular Simulation. 2020 Feb 11;46(3):169-85.
  12. Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimer’s disease. Rayala Swetha, Devendra Kumar, Sukesh K. Gupta, Ankit Ganeshpurkar, Gopichand Gutti, Dileep kumar, Ravi Singh, Srabanti Jana, Sairam Krishnamurthy, Sushil Kumar Singh. Future Medicinal Chemistry 11.24 (2019): 3161-3178.
  13. Discovery of novel series of 2-substituted benzo [d] oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease. Gopichand Gutti, Kakarla R, Devendra Kumar, Beohar M, Ankit Ganeshpurkar, Ashok Kumar, Krishnamurthy S, Sushil Kumar Singh. European journal of medicinal chemistry. 2019 Aug 14:111613.
  14. Development of pyrazole and spiropyrazoline analogs as multifunctional agents for treatment of Alzheimer’s disease. Gopichand Gutti, Devendra Kumar, Pankaj Paliwal, Ankit Ganeshpurkar, Khemraj Lahre, Ashok Kumar, Krishnamurthy S, Sushil Kumar Singh. Bioorganic Chemistry. 2019 Jun 24:103080.
  15. Identifying potential GluN2B subunit containing N-Methyl-d-aspartate receptor inhibitors: An integrative in silico and molecular modeling approach. Ravi Singh, Ankit Ganeshpurkar, Devendra Kumar, Dileep Kumar, Ashok Kumar & Sushil Kumar Singh. Journal of Biomolecular Structure and Dynamics. 2020 Jun 12;38(9):2533-45.
  16. Protein-Protein Interaction and Aggregation Inhibitors in Alzheimer’s disease. Ankit Ganeshpurkar, Rayala Swetha, Devendra Kumar, Gore Pravin Gangaram, Ravi Singh, Gopichand Gutti, Srabanti Jana, Dileep Kumar, Ashok Kumar, Sushil Kumar Singh. Curr Top Med Chem. 2019;19(7):501-533.
  17. Biological profiling of piperazinediones for the management of anxiety. Devendra Kumar, Gupta SK, Ganeshpurkar A, Singh R, Kumar D, Das N, Krishnamurthy S, Singh SK. Pharmacology Biochemistry and Behavior. 2019 Jan 1;176:63-71.

Professional memberships:

Association of Pharmaceutical Teachers of India (APTI)

Official email ID:

Official Phone No.: 91-02563 286545-51

Profile Link:


© Copyright 2024. Shri Vile Parle Kelavani Mandal (SVKM) All Rights Reserved.   Disclaimer  |  Privacy Policy